CoChat
Sign Up
Cited by 219

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement

Athyros, Vasilios G., Alexandrides, Theodore K., Bilianou, Helen, Cholongitas, Evangelos, Doumas, Michael, Ganotakis, Emmanuel S., Goudevenos, John, Elisaf, Moses S., Germanidis, Georgios, Giouleme, Olga, Karagiannis, Asterios, Karvounis, Charalambos, Katsiki, Niki, Kotsis, Vasilios, Kountouras, Jannis, Liberopoulos, Evangelos, Pitsavos, Christos, Polyzos, Stergios, Rallidis, Loukianos S., Richter, Dimitrios, Tsapas, Apostolos G., Tselepis, Alexandros D., Tsioufis, Konstantinos, Tziomalos, Konstantinos, Tzotzas, Themistoklis, Vasiliadis, Themistoklis G., Vlachopoulos, Charalambos, Mikhailidis, Dimitri P., Mantzoros, Christos·2017·Metabolism
DOI 10.1016/j.metabol.2017.02.014
Open this paper in CoChat — free account

Abstract

Non-alcoholic fatty liver disease (NAFLD), the most common liver disease, is characterized by accumulation of fat (>5% of the liver tissue), in the absence of alcohol abuse or other chronic liver diseases. It is closely related to the epidemic of obesity, metabolic syndrome or type 2 diabetes mellitus (T2DM). NAFLD can cause liver inflammation and progress to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis or hepatocellular cancer (HCC). Nevertheless, cardiovascular disease (CVD) is the most common cause of death in NAFLD/NASH patients. Current guidelines suggest the use of pioglitazone both in patients with T2DM and in those without. The use of statins, though considered safe by the guidelines, have very limited use; only 10% in high CVD risk patients are on statins by tertiary centers in the US. There are data from several animal studies, 5 post hoc analyses of prospective long-term survival studies, and 5 rather small biopsy proven NASH studies, one at baseline and on at the end of the study. All these studies provide data for biochemical and histological improvement of NAFLD/NASH with statins and in the clinical studies large reductions in CVD events in comparison with those also on statins and normal liver. Ezetimibe was also reported to improve NAFLD. Drugs currently in clinical trials seem to have potential for slowing down the evolution of NAFLD and for reducing liver- and CVD-related morbidity and mortality, but it will take time before they are ready to be…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.metabol.2017.02.014

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 96

  1. 2016, J Hepatol, 64, 1388
  2. Vernon, 2011, Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults, Aliment Pharmacol Ther, 34, 274, 10.1111/j.1365-2036.2011.04724.x · DOI
  3. Fazel, 2016, Epidemiology and natural history of non-alcoholic fatty liver disease, Metabolism, 65, 1017, 10.1016/j.metabol.2016.01.012 · DOI
  4. Seto, 2017, Nonalcoholic fatty liver disease in Asia: emerging perspectives, J Gastroenterol, 52, 164, 10.1007/s00535-016-1264-3 · DOI
  5. Valenti, 2016, Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?, Liver Int, 10.1111/liv.13185 · DOI · Paper page
  6. Berlanga, 2014, Molecular pathways in non-alcoholic fatty liver disease, Clin Exp Gastroenterol, 7, 221
  7. Buzzetti, 2016, The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD), Metabolism, 65, 1038, 10.1016/j.metabol.2015.12.012 · DOI · Paper page
  8. Polyzos, 2012, The emerging role of endocrine disruptors in pathogenesis of insulin resistance: a concept implicating nonalcoholic fatty liver disease, Curr Mol Med, 12, 68, 10.2174/156652412798376161 · DOI
  9. Polyzos, 2016, Adipokines in nonalcoholic fatty liver disease, Metabolism, 65, 1062, 10.1016/j.metabol.2015.11.006 · DOI
  10. Bechmann, 2012, The interaction of hepatic lipid and glucose metabolism in liver diseases, J Hepatol, 56, 952, 10.1016/j.jhep.2011.08.025 · DOI
  11. Marí, 2006, Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis, Cell Metab, 4, 185, 10.1016/j.cmet.2006.07.006 · DOI
  12. Polyzos, 2012, Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease, J Clin Gastroenterol, 46, 272, 10.1097/MCG.0b013e31824587e0 · DOI
  13. Kantartzis, 2012, Cardiovascular disease in patients with non-alcoholic fatty liver disease, Ann Gastroenterol, 25, 276
  14. Romiopoulos, 2014, Helicobacter pylori-related metabolic syndrome might justify earlier colorectal cancer screening, Gastrointest Endosc, 80, 188, 10.1016/j.gie.2014.01.054 · DOI
  15. Sanna, 2016, Non-alcoholic fatty liver disease and extra-hepatic cancers, Int J Mol Sci, 17, 10.3390/ijms17050717 · DOI
  16. Doycheva, 2013, Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes, J Diabetes Complications, 27, 293, 10.1016/j.jdiacomp.2012.10.008 · DOI
  17. Targher, 2016, Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis, J Hepatol, 65, 589, 10.1016/j.jhep.2016.05.013 · DOI
  18. VanWagner, 2015, Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study, Hepatology, 62, 773, 10.1002/hep.27869 · DOI
  19. VanWagner, 2014, Associations between nonalcoholic fatty liver disease and subclinical atherosclerosis in middle-aged adults: the Coronary Artery Risk Development in Young Adults Study, Atherosclerosis, 235, 599, 10.1016/j.atherosclerosis.2014.05.962 · DOI
  20. Pais, 2016, Fatty liver is an independent predictor of early carotid atherosclerosis, J Hepatol, 65, 95, 10.1016/j.jhep.2016.02.023 · DOI
  21. Fracanzani, 2016, Epicardial adipose tissue (EAT) thickness is associated with cardiovascular and liver damage in nonalcoholic fatty liver disease, PLoS One, 11, e0162473, 10.1371/journal.pone.0162473 · DOI
  22. Byrne, 2015, NAFLD: a multisystem disease, J Hepatol, 62, S47, 10.1016/j.jhep.2014.12.012 · DOI
  23. Alkhouri, 2016, Noninvasive diagnosis of nonalcoholic fatty liver disease: are we there yet?, Metabolism, 65, 1087, 10.1016/j.metabol.2016.01.013 · DOI
  24. Mencin, 2015, Caring for children with NAFLD and navigating their care into adulthood, Nat Rev Gastroenterol Hepatol, 12, 617, 10.1038/nrgastro.2015.146 · DOI
  25. Rinella, 2016, Management of NAFLD: a stage-based approach, Nat Rev Gastroenterol Hepatol, 13, 196, 10.1038/nrgastro.2016.3 · DOI
  26. Hardy, 2015, Nonalcoholic fatty liver disease: new treatments, Curr Opin Gastroenterol, 31, 175, 10.1097/MOG.0000000000000175 · DOI
  27. He, 2016, Thiazolidinediones for nonalcoholic steatohepatitis: a meta-analysis of randomized clinical trials, Medicine (Baltimore), 95, e494727, 10.1097/MD.0000000000004947 · DOI
  28. Ratziu, 2010, A position statement on NAFLD/NASH based on the EASL 2009 special conference, J Hepatol, 53, 372, 10.1016/j.jhep.2010.04.008 · DOI
  29. Chalasani, 2012, The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association, Hepatology, 55, 2005, 10.1002/hep.25762 · DOI
  30. Liao, 2017, Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis, BMJ Open, 7, e013927, 10.1136/bmjopen-2016-013927 · DOI · Paper page
  31. Spengler, 2015, Recommendations for diagnosis, referral for liver biopsy, and treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, Mayo Clin Proc, 90, 1233, 10.1016/j.mayocp.2015.06.013 · DOI
  32. Sahebkar, 2014, New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease, Expert Opin Pharmacother, 15, 493, 10.1517/14656566.2014.876992 · DOI
  33. Okada, 2013, Rosuvastatin ameliorates high-fat and high-cholesterol diet-induced nonalcoholic steatohepatitis in rats, Liver Int, 33, 301, 10.1111/liv.12033 · DOI
  34. Ji, 2011, Comparison of dietary control and atorvastatin on high fat diet induced hepatic steatosis and hyperlipidemia in rats, Lipids Health Dis, 10, 23, 10.1186/1476-511X-10-23 · DOI
  35. Seif El-Din, 2015, Effects of rosuvastatin and/or β-carotene on non-alcoholic fatty liver in rats, Res Pharm Sci, 10, 275
  36. Kabel, 2015, Ameliorative potential of omega 3 fatty acids and HMG-CoA reductase inhibitors on experimentally-induced non-alcoholic steatohepatitis, Prostaglandins Leukot Essent Fat Acids, 96, 1, 10.1016/j.plefa.2014.12.003 · DOI
  37. Matafome, 2011, Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia, Diabetes Metab Res Rev, 27, 54, 10.1002/dmrr.1157 · DOI
  38. Vilà, 2011, Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment, Toxicol Appl Pharmacol, 251, 32, 10.1016/j.taap.2010.11.011 · DOI
  39. Chong, 2015, Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells, BMC Gastroenterol, 15, 22, 10.1186/s12876-015-0248-8 · DOI
  40. Miyaki, 2011, Pitavastatin inhibits hepatic steatosis and fibrosis in non-alcoholic steatohepatitis model rats, Hepatol Res, 41, 375, 10.1111/j.1872-034X.2010.00769.x · DOI
  41. Athyros, 2010, Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study: a post-hoc analysis, Lancet, 376, 1916, 10.1016/S0140-6736(10)61272-X · DOI · Paper page
  42. Tikkanen, 2013, Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels, Int J Cardiol, 168, 3846, 10.1016/j.ijcard.2013.06.024 · DOI
  43. Athyros, 2017, Statins and non-alcoholic steatohepatitis, Metabolism, 66, e1, 10.1016/j.metabol.2016.10.006 · DOI
  44. Athyros, 2014, Are statins ‘IDEAL’ for non-alcoholic fatty liver disease?, Curr Med Res Opin, 30, 229, 10.1185/03007995.2013.855192 · DOI
  45. Tziomalos, 2012, Non-alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options, Curr Vasc Pharmacol, 10, 162, 10.2174/157016112799305012 · DOI
  46. Vlachopoulos, 2010, Increased arterial stiffness and impaired endothelial function in nonalcoholic fatty liver disease: a pilot study, Am J Hypertens, 23, 1183, 10.1038/ajh.2010.144 · DOI
  47. Athyros, 2011, Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women, Curr Vasc Pharmacol, 9, 647, 10.2174/157016111797484080 · DOI
  48. Athyros, 2006, Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study, Curr Med Res Opin, 22, 873, 10.1185/030079906X104696 · DOI
  49. Angulo, 2015, Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease, Gastroenterology, 149, 389, 10.1053/j.gastro.2015.04.043 · DOI · Paper page
  50. Lonardo, 2016, Non-alcoholic fatty liver disease and risk of cardiovascular disease, Metabolism, 65, 1136, 10.1016/j.metabol.2015.09.017 · DOI
  51. Rallidis, 2004, Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study, Atherosclerosis, 174, 193, 10.1016/j.atherosclerosis.2004.01.008 · DOI
  52. Hyogo, 2008, Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia, Metabolism, 57, 1711, 10.1016/j.metabol.2008.07.030 · DOI
  53. Kargiotis, 2014, Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report, Curr Vasc Pharmacol, 12, 505, 10.2174/15701611113119990009 · DOI · Paper page
  54. Kargiotis, 2015, Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome, World J Gastroenterol, 21, 7860, 10.3748/wjg.v21.i25.7860 · DOI
  55. Mintziori, 2016, Emerging and future therapies for nonalcoholic steatohepatitis in adults, Expert Opin Pharmacother, 17, 1937, 10.1080/14656566.2016.1225727 · DOI
  56. Sookoian, 2011, Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease, Hepatology, 53, 1883, 10.1002/hep.24283 · DOI
  57. Nascimbeni, 2016, Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease, BMJ Open Gastroenterol, 3, e000075, 10.1136/bmjgast-2015-000075 · DOI
  58. Eslami, 2013, Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, Cochrane Database Syst Rev, CD008623
  59. Singh, 2013, Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis, Gastroenterology, 144, 323, 10.1053/j.gastro.2012.10.005 · DOI
  60. Simon, 2016, Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: results from ERCHIVES, Hepatology, 64, 47, 10.1002/hep.28506 · DOI
  61. Kim, 2017, Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: a nationwide nested case–control study, Int J Cancer, 140, 798, 10.1002/ijc.30506 · DOI
  62. Polyzos, 2014, Irisin in patients with nonalcoholic fatty liver disease, Metabolism, 63, 207, 10.1016/j.metabol.2013.09.013 · DOI · Paper page
  63. Polyzos, 2016, Vaspin, resistin, retinol-binding protein-4, interleukin-1α and interleukin-6 in patients with nonalcoholic fatty liver disease, Ann Hepatol, 15, 705
  64. Cabrera, 2016, Diet-induced nonalcoholic fatty liver disease is associated with sarcopenia and decreased serum insulin-like growth factor-1, Dig Dis Sci, 61, 3190, 10.1007/s10620-016-4285-0 · DOI
  65. Deushi, 2016, Ezetimibe reduced hepatic steatosis induced by dietary oxysterols in nonhuman primates, FEBS Open Bio, 6, 1008, 10.1002/2211-5463.12107 · DOI
  66. Lee, 2016, Ezetimibe, an NPC1L1 inhibitor, is a potent Nrf2 activator that protects mice from diet-induced nonalcoholic steatohepatitis, Free Radic Biol Med, 99, 520, 10.1016/j.freeradbiomed.2016.09.009 · DOI
  67. Simon, 2016, Cardiovascular risk reduction in patients with nonalcoholic fatty liver disease: the potential role of ezetimibe, Dig Dis Sci, 61, 3425, 10.1007/s10620-016-4330-z · DOI
  68. Takeshita, 2014, The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial, Diabetologia, 57, 878, 10.1007/s00125-013-3149-9 · DOI
  69. Filippatos, 2011, Role of ezetimibe in non-alcoholic fatty liver disease, World J Hepatol, 3, 265, 10.4254/wjh.v3.i10.265 · DOI
  70. Katsiki, 2016, Non-alcoholic fatty liver disease and dyslipidemia: an update, Metabolism, 65, 1109, 10.1016/j.metabol.2016.05.003 · DOI · Paper page
  71. Lin, 2016, Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis: a secondary analysis of the MOZART trial, Therap Adv Gastroenterol, 9, 152, 10.1177/1756283X15621232 · DOI
  72. Loomba, 2015, Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial), Hepatology, 61, 1239, 10.1002/hep.27647 · DOI
  73. Averna, 2015, The effect of ezetimibe on NAFLD, Atheroscler Suppl, 17, 27, 10.1016/S1567-5688(15)50007-X · DOI
  74. Ruscica, 2016, Liver fat accumulation is associated with circulating PCSK9, Ann Med, 48, 384, 10.1080/07853890.2016.1188328 · DOI
  75. Ruscica, 2016, Suppressor of cytokine signaling-3 (SOCS-3) induces proprotein convertase subtilisin kexin type 9 (PCSK9) expression in hepatic HepG2 cell line, J Biol Chem, 291, 3508, 10.1074/jbc.M115.664706 · DOI
  76. Zhu, 2016, The potential mechanisms of berberine in the treatment of nonalcoholic fatty liver disease, Molecules, 21, 10.3390/molecules21101336 · DOI
  77. Anstee, 2010, Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis, J Hepatol, 53, 542, 10.1016/j.jhep.2010.03.016 · DOI
  78. Ratziu, 2012, A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis, Hepatology, 55, 419, 10.1002/hep.24747 · DOI
  79. Makri, 2016, Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease, World J Gastroenterol, 22, 9039, 10.3748/wjg.v22.i41.9039 · DOI
  80. Neuschwander-Tetri, 2015, Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial, Lancet, 385, 956, 10.1016/S0140-6736(14)61933-4 · DOI · Paper page
  81. Honda, 2016, The selective SGLT2 inhibitor Ipragliflozin has a therapeutic effect on nonalcoholic steatohepatitis in mice, PLoS One, 11, e0146337, 10.1371/journal.pone.0146337 · DOI
  82. Jojima, 2016, Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes, Diabetol Metab Syndr, 8, 45, 10.1186/s13098-016-0169-x · DOI
  83. Armstrong, 2016, Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study, Lancet, 387, 679, 10.1016/S0140-6736(15)00803-X · DOI · Paper page
  84. Tang, 2015, Effects of insulin glargine and liraglutide therapy on liver fat as measured by magnetic resonance in patients with type 2 diabetes: a randomized trial, Diabetes Care, 38, 1339, 10.2337/dc14-2548 · DOI
  85. Barreyro, 2015, The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis, Liver Int, 35, 953, 10.1111/liv.12570 · DOI
  86. Wan, 2016, Role of NLRP3 inflammasome in the progression of NAFLD to NASH, Can J Gastroenterol Hepatol, 2016, 6489012, 10.1155/2016/6489012 · DOI
  87. Tilg, 2016, IL-1 cytokine family members and various inflammasomes mediate different aspects of both ALD and NAFLD, Hepatology, 64, 955, 10.1002/hep.28456 · DOI
  88. Suzuki, 2009, Allopurinol, an inhibitor of uric acid synthesis-can it be used for the treatment of metabolic syndrome and related disorders?, Drugs Today (Barc), 45, 363, 10.1358/dot.2009.45.5.1370460 · DOI
  89. Cai, 2013, Serum uric acid levels and non-alcoholic fatty liver disease in Uyghur and Han ethnic groups in northwestern China, Arq Bras Endocrinol Metabol, 57, 617, 10.1590/S0004-27302013000800006 · DOI
  90. Salameh, 2016, PNPLA3 as a genetic determinant of risk for and severity of non-alcoholic fatty liver disease spectrum, J Clin Transl Hepatol, 4, 175
  91. Friedman, 2016, Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR phase 2b study design, Contemp Clin Trials, 47, 356, 10.1016/j.cct.2016.02.012 · DOI
  92. Liu, 2016, MicroRNAs as biomarkers and regulators of nonalcoholic fatty liver disease, J Dig Dis, 17, 708, 10.1111/1751-2980.12408 · DOI
  93. Di Mauro, 2016, Intracellular and extracellular miRNome deregulation in cellular models of NAFLD or NASH: clinical implications, Nutr Metab Cardiovasc Dis, 26, 1129, 10.1016/j.numecd.2016.08.004 · DOI
  94. Mahgoub, 2016, MicroRNAs in the evaluation and potential treatment of liver diseases, J Clin Med, 5, 10.3390/jcm5050052 · DOI
  95. Bader, 2012, Yes! Statins can be given to liver patients, J Hepatol, 56, 305, 10.1016/j.jhep.2011.08.016 · DOI
  96. Del Ben, 2017, Under-prescription of statins in patients with non-alcoholic fatty liver disease, Nutr Metab Cardiovasc Dis, 27, 161, 10.1016/j.numecd.2016.09.011 · DOI

Cited by

Sorted by citations

Metadata

Authors
Athyros, V. G., Alexandrides, T. K., Bilianou, H., Cholongitas, E., Doumas, M., Ganotakis, E. S., Goudevenos, J., Elisaf, M. S., Germanidis, G., Giouleme, O., Karagiannis, A., Karvounis, C., Katsiki, N., Kotsis, V., Kountouras, J., Liberopoulos, E., Pitsavos, C., Polyzos, S., Rallidis, L. S., Richter, D., Tsapas, A. G., Tselepis, A. D., Tsioufis, K., Tziomalos, K., Tzotzas, T., Vasiliadis, T. G., Vlachopoulos, C., Mikhailidis, D. P., & Mantzoros, C.
Venue
Metabolism
Publisher
Elsevier BV
Published
2017-06
Volume
71
Pages
17-32
ISSN
0026-0495
DOI
10.1016/j.metabol.2017.02.014
Cited by
219
References
8
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review